“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors and Accelerate the Development of Potentially Lifesaving Therapies
May 26, 2020-Fort Washington, PA: Ashfield, part of UDG Healthcare plc, a global leader in commercialization services for the pharmaceutical and healthcare industry, is pleased to announce today that it is part of the national “The Fight Is In Us” campaign working to mobilize people in the United States who have recovered from COVID-19 to donate their blood plasma. Ashfield is proud to provide contact center support to the coalition’s national campaign seeking blood plasma donors with the coalition’s shared goal of accelerating the development of life saving therapies.
World-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups have come together under The Fight Is In Us campaign. Partners in this coalition include Microsoft, Takeda, CSL Behring, Mayo Clinic, Octapharma and Uber Health among many others.
The Fight Is In Us campaign is working against a significant and urgent timeline, which is to recruit COVID-19 survivors within two months of their recovery to ensure that their blood plasma contains a robust enough concentration of antibodies to have a positive effect, and to address the substantial seasonal increase in COVID-19 cases anticipated this fall in the Northern Hemisphere by the Centers for Disease Control and Prevention (CDC) and other public health experts.
Communicators at the Ashfield Medical Information contact center will provide inbound telephone support, addressing the questions and concerns of COVID-19 survivors who are interested in getting involved and have called the nationally advertised toll-free hotline associated with The Fight Is In Us campaign: 844-4FIGHT4U. Amy Van Sant, President of Ashfield Medical Affairs, US, remarked, “Our Communicators have been effectively working remotely during the COVID-19 pandemic and we have the agility to mobilize while upholding our signature standards in quality. We are delighted to be able to lend our industry leading contact center to this important effort.”
The Fight Is In Us coalition partners are working on two distinct approaches for potentially treating COVID-19 that both urgently require collection of convalescent plasma. One approach is the direct transfusion of blood plasma though the Expanded Access Program for convalescent plasma, which is currently being administered with authorization from the Food & Drug Administration by Mayo Clinic. Its safety and efficacy are currently being evaluated through multiple clinical trials in different populations. Blood donor centers throughout the country are currently collecting convalescent plasma from COVID-19 survivors for this purpose. The other approach is the development of a medicine known as a hyperimmune globulin (H-Ig), which is being manufactured now and is targeted to be studied in clinical trials this summer. Through the manufacturing process, the plasma is pooled, concentrated and purified, resulting in a vial of medicine with consistent levels of antibodies that is easy to store, distribute and administer to patients.
“Ashfield is extremely proud to be part of this collaborative partnership in the fight against COVID-19. Patients are at the core of the healthcare services that we provide, and we’re passionate about leveraging our industry-leading contact center service to support COVID-19 survivors,” stated Greg Flynn, Global President, Ashfield Commercial and Patient Solutions. “We are committed to supporting the survivors who will be participating in this critical campaign to donate their plasma.”